| Literature DB >> 35834819 |
Francesco Bavo1,2, Marco Pallavicini1, Susanna Pucci3,4, Rebecca Appiani1, Alessandro Giraudo1, Brek Eaton5, Linda Lucero5, Cecilia Gotti3, Milena Moretti3,6, Paul Whiteaker7, Cristiano Bolchi1.
Abstract
Nicotinic acetylcholine receptors containing α9 subunits (α9*-nAChRs) are potential druggable targets arousing great interest for pain treatment alternative to opioids. Nonpeptidic small molecules selectively acting as α9*-nAChRs antagonists still remain an unattained goal. Here, through modifications of the cationic head and the ethylene linker, we have converted the 2-triethylammonium ethyl ether of 4-stilbenol (MG624), a well-known α7- and α9*-nAChRs antagonist, into some selective antagonists of human α9*-nAChR. Among these, the compound with cyclohexyldimethylammonium head (7) stands out for having no α7-nAChR agonist or antagonist effect along with very low affinity at both α7- and α3β4-nAChRs. At supra-micromolar concentrations, 7 and the other selective α9* antagonists behaved as partial agonists at α9*-nAChRs with a very brief response, followed by rebound current once the application is stopped and the channel is disengaged. The small or null postapplication activity of ACh seems to be related to the slow recovery of the rebound current.Entities:
Mesh:
Substances:
Year: 2022 PMID: 35834819 PMCID: PMC9339509 DOI: 10.1021/acs.jmedchem.2c00746
Source DB: PubMed Journal: J Med Chem ISSN: 0022-2623 Impact factor: 8.039